These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311 [TBL] [Abstract][Full Text] [Related]
3. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]
5. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
6. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012600. PubMed ID: 28295158 [TBL] [Abstract][Full Text] [Related]
7. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation]. Chen X; Chang Y; Cui HY; Ren CC; Yu BY Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556 [TBL] [Abstract][Full Text] [Related]
8. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Perni SC; Predanic M; Kalish RB; Chervenak FA; Chasen ST Am J Obstet Gynecol; 2006 Jan; 194(1):127-30. PubMed ID: 16389021 [TBL] [Abstract][Full Text] [Related]
9. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230 [TBL] [Abstract][Full Text] [Related]
10. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. Spencer K; Nicolaides KH BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267 [TBL] [Abstract][Full Text] [Related]
19. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Wald NJ; Hackshaw AK Prenat Diagn; 1997 Sep; 17(9):821-9. PubMed ID: 9316126 [TBL] [Abstract][Full Text] [Related]
20. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A. Spencer K BJOG; 2001 Oct; 108(10):1043-6. PubMed ID: 11702835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]